Tertiary Nav - Press Releases Press ReleasesMedia Statements Press Releases Items Per Page 102550 News Category Business & FinancialCitizenshipEarningsMedia StatementProduct NewsRecognitionRegulatoryScience & Innovation Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Date Title 3/25/10 AVI BioPharma Announces Update on AVI-5038, Its PPMO Duchenne Muscular Dystrophy Drug Candidate, to Be Presented April 14, 2010 at the American Academy of Neurology Annual Meeting 3/16/10 AVI BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results 3/9/10 AVI BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Corporate Update Conference Call 2/15/10 AVI BioPharma Receives Grants Totaling $500,000 from CureDuchenne and the Foundation to Eradicate Duchenne to Support Continuing Development of Drug Candidates to Treat Duchenne Muscular Dystrophy 2/5/10 AVI BioPharma's Drug Candidate AVI-5038 Receives European Orphan Drug Designation For Duchenne Muscular Dystrophy 2/4/10 AVI BioPharma GLP Safety Pharmacology and Genotoxicity Evaluations of AVI-4658 for Duchenne Muscular Dystrophy Published in the International Journal of Toxicology 1/15/10 TMTI Accomplishments Have Advanced the Nation's Ability to Successfully Counter an Emerging Biothreat 12/22/09 Systemic Treatment with AVI-4658 Demonstrates RNA Exon Skipping and Dystrophin Protein Expression in Duchenne Muscular Dystrophy Patients 11/19/09 AVI BioPharma, Inc. Presents Update on AVI-4658 at TREAT-NMD / NIH International Conference 11/18/09 AVI BioPharma, Inc. to Present at Transformational Medical Technologies Initiative (TMTI) Industry Day Pagination First page « first Previous page ‹ previous … Page 61 Page 62 Page 63 Page 64 Current page 65 Page 66 Page 67 Page 68 Page 69 … Next page next › Last page last » Displaying 641 - 650 of 816 Toolkit Print Page | Email Alerts | RSS Feeds | Contacts
Press Releases Items Per Page 102550 News Category Business & FinancialCitizenshipEarningsMedia StatementProduct NewsRecognitionRegulatoryScience & Innovation Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Date Title 3/25/10 AVI BioPharma Announces Update on AVI-5038, Its PPMO Duchenne Muscular Dystrophy Drug Candidate, to Be Presented April 14, 2010 at the American Academy of Neurology Annual Meeting 3/16/10 AVI BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results 3/9/10 AVI BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Corporate Update Conference Call 2/15/10 AVI BioPharma Receives Grants Totaling $500,000 from CureDuchenne and the Foundation to Eradicate Duchenne to Support Continuing Development of Drug Candidates to Treat Duchenne Muscular Dystrophy 2/5/10 AVI BioPharma's Drug Candidate AVI-5038 Receives European Orphan Drug Designation For Duchenne Muscular Dystrophy 2/4/10 AVI BioPharma GLP Safety Pharmacology and Genotoxicity Evaluations of AVI-4658 for Duchenne Muscular Dystrophy Published in the International Journal of Toxicology 1/15/10 TMTI Accomplishments Have Advanced the Nation's Ability to Successfully Counter an Emerging Biothreat 12/22/09 Systemic Treatment with AVI-4658 Demonstrates RNA Exon Skipping and Dystrophin Protein Expression in Duchenne Muscular Dystrophy Patients 11/19/09 AVI BioPharma, Inc. Presents Update on AVI-4658 at TREAT-NMD / NIH International Conference 11/18/09 AVI BioPharma, Inc. to Present at Transformational Medical Technologies Initiative (TMTI) Industry Day Pagination First page « first Previous page ‹ previous … Page 61 Page 62 Page 63 Page 64 Current page 65 Page 66 Page 67 Page 68 Page 69 … Next page next › Last page last » Displaying 641 - 650 of 816